Richard J Edmondson
Overview
Explore the profile of Richard J Edmondson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1575
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morgan R, Wang X, Barnes B, Spurgeon L, Carrot A, Netto D, et al.
Br J Cancer
. 2024 Nov;
131(12):1919-1927.
PMID: 39550490
Background: High-grade serous ovarian cancer (HGSOC) can be treated with platinum-based neoadjuvant chemotherapy (NACT) and delayed primary surgery (DPS). Histopathological response to NACT can be assessed using Böhm's chemotherapy response...
2.
McCormick A, Donoghue P, Dixon M, OSullivan R, ODonnell R, Murray J, et al.
Clin Cancer Res
. 2024 Aug;
30(16):3640.
PMID: 39143885
No abstract available.
3.
Zanjirband M, Curtin N, Edmondson R, Lunec J
Oncotarget
. 2024 Feb;
15:142.
PMID: 38386812
No abstract available.
4.
Walker T, Faraahi Z, Price M, Hawarden A, Waddell C, Russell B, et al.
Br J Cancer
. 2023 Feb;
128(9):1765-1776.
PMID: 36810910
Background: Ovarian cancers are hallmarked by chromosomal instability. New therapies deliver improved patient outcomes in relevant phenotypes, however therapy resistance and poor long-term survival signal requirements for better patient preselection....
5.
Morgan R, Clamp A, White D, Price M, Burghel G, Ryder W, et al.
Clin Cancer Res
. 2023 Feb;
29(14):2602-2611.
PMID: 36799931
Purpose: A single maintenance course of a PARP inhibitor (PARPi) improves progression-free survival (PFS) in germline BRCA1/2-mutant high-grade serous ovarian cancer (gBRCAm-HGSOC). The feasibility of a second maintenance course of...
6.
Morgan R, Burghel G, Flaum N, Bulman M, Smith P, Clamp A, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765687
Women diagnosed with non-mucinous high-grade epithelial ovarian cancer (EOC) in England are often reflex-tested for germline and tumour / variants. The value of germline testing in women diagnosed aged ≥80...
7.
Cummins C, Kumar S, Long J, Balega J, Broadhead T, Duncan T, et al.
Cancers (Basel)
. 2022 Sep;
14(18).
PMID: 36139523
We investigated URS and impact on survival in whole patient cohorts with AOC treated within gynaecological cancer centres that participated in the previously presented SOCQER 2 study. National cancer registry...
8.
Vermij L, Leon-Castillo A, Singh N, Powell M, Edmondson R, Genestie C, et al.
Mod Pathol
. 2022 Jun;
35(10):1475-1483.
PMID: 35752743
Standard molecular classification of endometrial cancers (EC) is now endorsed by the WHO and identifies p53-abnormal (p53abn) EC as the subgroup with the poorest prognosis and the most likely to...
9.
Morgan R, Burghel G, Flaum N, Bulman M, Smith P, Clamp A, et al.
J Clin Pathol
. 2022 Jun;
76(10):684-689.
PMID: 35738887
Aims: Clinical guidelines recommend testing both germline and tumour DNA for pathogenic variants (PVs) in non-mucinous high-grade epithelial ovarian cancer (NMEOC). In this study, we show that some tumour PVs...
10.
Sentance J, Stocking K, Edmondson R, Kearney R
Int Urogynecol J
. 2022 Mar;
33(11):3129-3136.
PMID: 35267060
Introduction And Hypothesis: Obstructive defecation syndrome (ODS) is a common urogynaecology presentation. This study compares two questionnaires, the electronic Personal Assessment Questionnaire (e-PAQ), used in urogynaecology clinics, with the ODS-Score...